1
|
Chick RC, Adams AM, Peace KM, Kemp Bohan PM, Schwantes IR, Clifton GT, Vicente D, Propper B, Newhook T, Grubbs EG, Bednarski BK, Vreeland TJ. Using the Flipped Classroom Model in Surgical Education: Efficacy and Trainee Perception. J Surg Educ 2021; 78:1803-1807. [PMID: 34210646 DOI: 10.1016/j.jsurg.2021.05.008] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/21/2020] [Revised: 04/03/2021] [Accepted: 05/23/2021] [Indexed: 06/13/2023]
Abstract
OBJECTIVE To describe the feasibility, efficacy, and learner perception of the flipped classroom model for teaching conferences within surgical training programs. DESIGN For the flipped classroom conferences, video lectures were prepared by a faculty member, and sent to all attendees at least 2 days prior to lecture. The conference time was then spent going over cases and questions, rather than traditional lecture. We conducted a qualitative survey to assess learner's perceptions and pre-lecture quizzes to assess trainee preparedness. SETTING The comparison of pre-conference quizzes between flipped classroom and traditional models was carried out at Brooke Army Medical Center (BAMC) in San Antonio, TX, a tertiary care facility with a general surgery residency program. The survey was conducted at BAMC and within the Complex General Surgical Oncology fellowship program at University of Texas MD Anderson Cancer Center, where a flipped classroom model was similarly employed. PARTICIPANTS Surgical residents BAMC participated in pre-lecture quizzes. BAMC residents and MD Anderson fellows were invited to complete the online survey. RESULTS Lecture videos did not increase mean preparation time (1.53 vs. 1.46 hours without vs. with video, p = 0.858), but did increase mean quiz scores from 67% to 80% (p = 0.031) with 32/35 learners utilizing videos. Videos increased the proportion of learners who self-reported preparing at all from 42% to 95% (p = 0.28), and preparing for at least one hour for conference from 23% to 49% (p = 0.014). Of survey respondents, 90% said videos were very helpful, 90% would use them weekly if available, and 90% prefer this format to traditional lecture. CONCLUSIONS Utilization of a flipped classroom method was well received and preferred by surgical trainees, and it increased performance on pre-conference quizzes without increasing preparation time. Although creation of video lectures is work-intensive for lecturers, these results suggest it is more effective for learner preparation. These results could be generalizable to surgical residents nationwide as technology utilization increases in surgical education.
Collapse
Affiliation(s)
- R C Chick
- US Army Brooke Army Medical Center, San Antonio, Texas
| | - A M Adams
- US Army Brooke Army Medical Center, San Antonio, Texas.
| | - K M Peace
- US Army Brooke Army Medical Center, San Antonio, Texas
| | | | - I R Schwantes
- Carver College of Medicine, University of Iowa, Iowa City, Lowa
| | - G T Clifton
- US Army Brooke Army Medical Center, San Antonio, Texas
| | - D Vicente
- Naval Medical Center San Diego, San Diego, California
| | - B Propper
- US Army Brooke Army Medical Center, San Antonio, Texas
| | - T Newhook
- University of Texas MD Anderson Cancer Center, Houston, Texas
| | - E G Grubbs
- University of Texas MD Anderson Cancer Center, Houston, Texas
| | - B K Bednarski
- University of Texas MD Anderson Cancer Center, Houston, Texas
| | - T J Vreeland
- US Army Brooke Army Medical Center, San Antonio, Texas
| |
Collapse
|
2
|
Clifton GT, Kemp Bohan PM, Hale DF, Myers JW, Brown TA, Holmes JP, Vreeland TJ, Litton JK, Murthy RK, Mittendorf EA, Peoples GE. Abstract P2-09-01: Subgroups analysis of a multicenter, prospective, randomized, blinded phase 2b trial of trastuzumab + nelipeptimut-S (NeuVax) vs trastuzumab for prevention of recurrence in breast cancer patients. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p2-09-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:HER2 low-expressing (LE) (IHC 1-2+, FISH non-amplified) breast cancer (BC) patients (pts) have not benefited from HER2-directed therapy despite HER2 antigen availability. Triple negative BC (TNBC), in particular, is immunogenic and in need of additional therapeutic options. We have previously shown the HER2-derived nelipeptimut-S (E75) + GM-CSF (NeuVax) to be synergistic with trastuzumab (Tz) in pre-clinical and pilot clinical studies. In a planned interim analysis of a multi-center, prospective, randomized, single-blinded, placebo-controlled phase 2b trial of Tz + NeuVax vs Tz to reduce recurrence in HER2 LE, node-positive (NP) and/or triple negative BC (TNBC) pts, we previously reported that the NeuVax + Tz was safe without added cardiac toxicity and demonstrated a significant reduction of recurrences in TNBC pts. This analysis examines additional subsets in this trial.
Methods:HER2 LE, NP and/or TNBC pts who were clinically disease-free after standard therapy were randomized to receive Tz+NeuVax (vaccine group; VG) or Tz+GM-CSF (control group; CG). All pts received 1 yr of Tz per label. NeuVax or GM-CSF was given every 3 weeks x 6 starting with the 3rdTz dose, and then boosted every 6 months x 4. This pre-specified interim analysis was triggered 6 months after last enrollment. The primary endpoint is intention-to-treat 24 month disease-free survival (DFS) evaluated by log rank.
Results: Of 275 pts randomized in the study (VG n=136, CG n=139), 98 had TNBC (VG=53, CG=45). In the interim analysis, estimated disease-free survival (DFS) was assessed with a median follow up of 18.8 months. No significant clinicopathologic differences were seen between treatment groups. In the TNBC group, estimated DFS was higher overall in VG vs CG (91.9% v 69.9%, p=0.023; hazard ratio [HR] 0.29, 95% confidence interval [CI] 0.09-0.90). On TNBC subgroup analysis, estimated DFS was higher in VG vs CG among pts who received neoadjuvant chemotherapy (VG n=35, CG n=31; HR 0.26, CI 0.07-0.93; p=0.03), HER2 IHC 1+ BC (VG n=34, CG n=28; HR 0.20, CI 0.04-0.96; p=0.03), pts who were AJCC 7thedition stage I/II (VG n=37, CG n=27; HR incalculable, no recurrences in the VG, p=0.008), and pts 351yr of age (VG n=32 & CG n = 26; HR 0.26 CI 0.07,0.94; p=0.009). HRs did not appreciably vary based on the histologic grade or presence of lymphovascular invasion.
Conclusion:Examining the subgroups from the pre-specified interim analysis demonstrates a highly significant clinical benefit in TNBC pts overall. Within the TNBC cohort, specific benefit was seen in pts who received chemotherapy neoadjuvantly, expressed lower HER2, were earlier stage, and were older in age. These factors may help enrich the TNBC population targeted in a definitive Phase 3 study in TNBC patients with residual disease after neoadjuvant chemotherapy.
Citation Format: Clifton GT, Kemp Bohan PM, Hale DF, Myers JW, Brown TA, Holmes JP, Vreeland TJ, Litton JK, Murthy RK, Mittendorf EA, Peoples GE. Subgroups analysis of a multicenter, prospective, randomized, blinded phase 2b trial of trastuzumab + nelipeptimut-S (NeuVax) vs trastuzumab for prevention of recurrence in breast cancer patients [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P2-09-01.
Collapse
Affiliation(s)
- GT Clifton
- Brooke Army Medical Center, Fort Sam Houston, TX; St. Joseph Hospital, Santa Rosa, CA; MD Anderson Cancer Center, Houston, TX; Brigham and Women's Hospital, Boston, MA; Uniformed Services University of the Health Sciences, Bethesda, MD
| | - PM Kemp Bohan
- Brooke Army Medical Center, Fort Sam Houston, TX; St. Joseph Hospital, Santa Rosa, CA; MD Anderson Cancer Center, Houston, TX; Brigham and Women's Hospital, Boston, MA; Uniformed Services University of the Health Sciences, Bethesda, MD
| | - DF Hale
- Brooke Army Medical Center, Fort Sam Houston, TX; St. Joseph Hospital, Santa Rosa, CA; MD Anderson Cancer Center, Houston, TX; Brigham and Women's Hospital, Boston, MA; Uniformed Services University of the Health Sciences, Bethesda, MD
| | - JW Myers
- Brooke Army Medical Center, Fort Sam Houston, TX; St. Joseph Hospital, Santa Rosa, CA; MD Anderson Cancer Center, Houston, TX; Brigham and Women's Hospital, Boston, MA; Uniformed Services University of the Health Sciences, Bethesda, MD
| | - TA Brown
- Brooke Army Medical Center, Fort Sam Houston, TX; St. Joseph Hospital, Santa Rosa, CA; MD Anderson Cancer Center, Houston, TX; Brigham and Women's Hospital, Boston, MA; Uniformed Services University of the Health Sciences, Bethesda, MD
| | - JP Holmes
- Brooke Army Medical Center, Fort Sam Houston, TX; St. Joseph Hospital, Santa Rosa, CA; MD Anderson Cancer Center, Houston, TX; Brigham and Women's Hospital, Boston, MA; Uniformed Services University of the Health Sciences, Bethesda, MD
| | - TJ Vreeland
- Brooke Army Medical Center, Fort Sam Houston, TX; St. Joseph Hospital, Santa Rosa, CA; MD Anderson Cancer Center, Houston, TX; Brigham and Women's Hospital, Boston, MA; Uniformed Services University of the Health Sciences, Bethesda, MD
| | - JK Litton
- Brooke Army Medical Center, Fort Sam Houston, TX; St. Joseph Hospital, Santa Rosa, CA; MD Anderson Cancer Center, Houston, TX; Brigham and Women's Hospital, Boston, MA; Uniformed Services University of the Health Sciences, Bethesda, MD
| | - RK Murthy
- Brooke Army Medical Center, Fort Sam Houston, TX; St. Joseph Hospital, Santa Rosa, CA; MD Anderson Cancer Center, Houston, TX; Brigham and Women's Hospital, Boston, MA; Uniformed Services University of the Health Sciences, Bethesda, MD
| | - EA Mittendorf
- Brooke Army Medical Center, Fort Sam Houston, TX; St. Joseph Hospital, Santa Rosa, CA; MD Anderson Cancer Center, Houston, TX; Brigham and Women's Hospital, Boston, MA; Uniformed Services University of the Health Sciences, Bethesda, MD
| | - GE Peoples
- Brooke Army Medical Center, Fort Sam Houston, TX; St. Joseph Hospital, Santa Rosa, CA; MD Anderson Cancer Center, Houston, TX; Brigham and Women's Hospital, Boston, MA; Uniformed Services University of the Health Sciences, Bethesda, MD
| |
Collapse
|
3
|
Berry JS, Vreeland TJ, Hale DF, Jackson DO, Trappey AF, Greene JM, Hardin MO, Herbert GS, Clifton GT, Peoples GE. Evaluation of Attenuated Tumor Antigens and the Implications for Peptide-Based Cancer Vaccine Development. J Cancer 2017; 8:1255-1262. [PMID: 28607601 PMCID: PMC5463441 DOI: 10.7150/jca.16450] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2016] [Accepted: 02/14/2017] [Indexed: 11/15/2022] Open
Abstract
INTRODUCTION: Peptide vaccines offer anti-tumor efficacy with very low toxicity. However, repeat stimulation with an immunogenic peptide leads to activation induced cell death (AICD), decreasing efficacy. We engineered variants of an immunogenic peptide (E39) and tested their ability to induce a robust, sustainable immune response. METHODS: Multiple variants of E39 were created by exchanging 1 or 2 amino acids. We tested the PBMC proliferation, cytokine production and cytolytic activity induced by each variant peptide. RESULTS: Repeated stimulation with E39 likely led to in vitro AICD, while stimulation with E39' led to T-cell proliferation with less evidence of AICD, modest cytokine production and high CTL activity. CONCLUSIONS: E39' appears to be the optimal variant of E39 for inducing effective long-term immunity.
Collapse
Affiliation(s)
- J S Berry
- Department of Surgery, Division of Colon and Rectal Surgery, Washington University, St. Louis, MO
| | - T J Vreeland
- Department of Surgery, Womack Army Medical Center, Fort Bragg, NC
| | - D F Hale
- Department of Surgery, Division of Colon and Rectal Surgery, Washington University, St. Louis, MO
| | - D O Jackson
- Department of Surgery, Brooke Army Medical Center, Fort Sam Houston, TX
| | - A F Trappey
- Department of Surgery, Brooke Army Medical Center, Fort Sam Houston, TX
| | - J M Greene
- Department of Surgery, Brooke Army Medical Center, Fort Sam Houston, TX
| | - M O Hardin
- Department of Surgery, Madigan Army Medical Center, Fort Lewis, WA
| | - G S Herbert
- Department of Surgery, Brooke Army Medical Center, Fort Sam Houston, TX
| | - G T Clifton
- Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX
| | - G E Peoples
- Cancer Vaccine Development Program, San Antonio, TX and Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD
| |
Collapse
|
4
|
Jackson DO, Qiao N, Peace KM, Hale DF, Vreeland TJ, Greene JM, Berry JS, Trappey AF, Clifton GT, Ibrahim N, Toms A, Peoples GE, Mittendorf EA. Abstract P6-10-04: Determining the optimal vaccination strategy using a combination of the folate binding protein (FBP) peptide vaccine (E39+GM-CSF) and an attenuated version (E39') to maximize the immunologic response in breast cancer patients. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p6-10-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND FBP is overexpressed in 20-50% of breast(B) cancers(Ca) and roughly 90% of endometrial(E) and ovarian (Ov) Ca. E39 (FBP191-199, EIWTHSYKV)+GM-CSF is an HLA-A2 restricted FBP peptide vaccine, which has been shown to generate significant in vivo immunologic response(IR) in a phase I/IIa trial in E Ca and Ov Ca patients (pts). There is a risk of inducing immunologic tolerance after multiple inoculations with a highly immunogenic vaccine. Thus, we are investigating a novel vaccination series using combinations of E39 and E39' (EIWTFSTKV, an attenuated version of E39) in a phase Ib, randomized, single-center trial. We are assessing short and long-term IR. Here, we present the initial IR analysis to the primary vaccination series (PVS) within B Ca pts.
METHODS HLA-A2 positive B or Ov Ca pts were enrolled after completion of standard of care therapy and randomized into three arms: EE (6 inoculations of E39); EE'(3 inoculations of E39, then 3 of E39'); or E'E(3 of E39', then 3 of E39). Theoretically, due to lower FBP expression and less aggressive chemotherapy regimens, B Ca pts are more antigen naïve and have a less suppressed immune system. Thus, only B Ca pts were included in this analysis. The PVS includes 6 inoculations total (R1-R6), one every 3-4 weeks, and containing 250mcg GM-CSF+500mcg peptide in the first 5 pts per arm and 1000mcg of peptide in second 5 pts. To assess the in vivo IR, local reaction(LR) was measured 48 hours after each inoculation (R1-R6), and delayed type hypersensitivity(DTH) was measured pre-PVS (R0), 1, and 6-months post-PVS (RC1, RC6). Ex vivo IR was measured via dextramer assay for E39-specific CD8+ T-cells at R0, RC1, and RC6. Statistical analyses were completed using appropriate tests.
RESULTS Thirty-five B Ca pts were enrolled, with 27 completing the PVS (EE n=10, EE' n=8, E'E n=9). No clinicopathologic differences between groups or significant toxicities > grade 2 were appreciated. LR increased from R1 to R6 in all groups (ΔEE= 24.80mm, p=0.14; ΔEE'=38.13mm, p=0.07; ΔE'E=8.05mm, p=0.38), the greatest increase approaching statistical significance in the EE' arm. The only arm with a statistically significant increase for in vivo DTH from R0-RC1-RC6 was in the EE' arm (ΔEE=-6.17mm, p=0.27; ΔEE'= 44.58mm, p<0.05; ΔE'E=-1.42, p=0.37). Ex vivo analysis of IR revealed no significant difference between groups at R0(p=0.45) or RC6(p=0.72), nor within groups over time (EE p=0.32, EE' p=0.47, E'E p=0.30).
CONCLUSION In this phase Ib trial analyzing the IR of B Ca pts receiving a different vaccination strategy, both peptides were noted to be safe and immunogenic. While no difference was seen in E39-specific CD8+ T cells between groups, the in vivo response was enhanced with the use of E39' after E39; this may indicate expansion of more effective clonal populations of CD8+ T cells with this strategy. These results may be specific to B Ca pts who are relatively antigen-naïve with relatively intact immune systems. Further analysis of these pts as this trial continues will determine the optimal vaccination strategy capable of stimulating and maintaining an IR to prevent B Ca recurrence.
Citation Format: Jackson DO, Qiao N, Peace KM, Hale DF, Vreeland TJ, Greene JM, Berry JS, Trappey AF, Clifton GT, Ibrahim N, Toms A, Peoples GE, Mittendorf EA. Determining the optimal vaccination strategy using a combination of the folate binding protein (FBP) peptide vaccine (E39+GM-CSF) and an attenuated version (E39') to maximize the immunologic response in breast cancer patients [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P6-10-04.
Collapse
Affiliation(s)
- DO Jackson
- San Antonio Militay Medical Center, San Antonio, TX; University of Texas MD Anderson Cancer Center, Houston, TX; Womack Army Medical Center, Fayetteville, NC; Cancer Vaccine Development Program, San Antonio, TX
| | - N Qiao
- San Antonio Militay Medical Center, San Antonio, TX; University of Texas MD Anderson Cancer Center, Houston, TX; Womack Army Medical Center, Fayetteville, NC; Cancer Vaccine Development Program, San Antonio, TX
| | - KM Peace
- San Antonio Militay Medical Center, San Antonio, TX; University of Texas MD Anderson Cancer Center, Houston, TX; Womack Army Medical Center, Fayetteville, NC; Cancer Vaccine Development Program, San Antonio, TX
| | - DF Hale
- San Antonio Militay Medical Center, San Antonio, TX; University of Texas MD Anderson Cancer Center, Houston, TX; Womack Army Medical Center, Fayetteville, NC; Cancer Vaccine Development Program, San Antonio, TX
| | - TJ Vreeland
- San Antonio Militay Medical Center, San Antonio, TX; University of Texas MD Anderson Cancer Center, Houston, TX; Womack Army Medical Center, Fayetteville, NC; Cancer Vaccine Development Program, San Antonio, TX
| | - JM Greene
- San Antonio Militay Medical Center, San Antonio, TX; University of Texas MD Anderson Cancer Center, Houston, TX; Womack Army Medical Center, Fayetteville, NC; Cancer Vaccine Development Program, San Antonio, TX
| | - JS Berry
- San Antonio Militay Medical Center, San Antonio, TX; University of Texas MD Anderson Cancer Center, Houston, TX; Womack Army Medical Center, Fayetteville, NC; Cancer Vaccine Development Program, San Antonio, TX
| | - AF Trappey
- San Antonio Militay Medical Center, San Antonio, TX; University of Texas MD Anderson Cancer Center, Houston, TX; Womack Army Medical Center, Fayetteville, NC; Cancer Vaccine Development Program, San Antonio, TX
| | - GT Clifton
- San Antonio Militay Medical Center, San Antonio, TX; University of Texas MD Anderson Cancer Center, Houston, TX; Womack Army Medical Center, Fayetteville, NC; Cancer Vaccine Development Program, San Antonio, TX
| | - N Ibrahim
- San Antonio Militay Medical Center, San Antonio, TX; University of Texas MD Anderson Cancer Center, Houston, TX; Womack Army Medical Center, Fayetteville, NC; Cancer Vaccine Development Program, San Antonio, TX
| | - A Toms
- San Antonio Militay Medical Center, San Antonio, TX; University of Texas MD Anderson Cancer Center, Houston, TX; Womack Army Medical Center, Fayetteville, NC; Cancer Vaccine Development Program, San Antonio, TX
| | - GE Peoples
- San Antonio Militay Medical Center, San Antonio, TX; University of Texas MD Anderson Cancer Center, Houston, TX; Womack Army Medical Center, Fayetteville, NC; Cancer Vaccine Development Program, San Antonio, TX
| | - EA Mittendorf
- San Antonio Militay Medical Center, San Antonio, TX; University of Texas MD Anderson Cancer Center, Houston, TX; Womack Army Medical Center, Fayetteville, NC; Cancer Vaccine Development Program, San Antonio, TX
| |
Collapse
|
5
|
Vreeland TJ, Clifton GT, Herbert GS, Hale DF, Jackson DO, Berry JS, Peoples GE. Gaining ground on a cure through synergy: combining checkpoint inhibitors with cancer vaccines. Expert Rev Clin Immunol 2016; 12:1347-1357. [PMID: 27323245 DOI: 10.1080/1744666x.2016.1202114] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
INTRODUCTION The approval of multiple checkpoint inhibitors (CPIs) for the treatment of advanced malignancies has sparked an explosion of research in the field of cancer immunotherapy. Despite the success of these medications, a large number of patients with advanced malignancy do not benefit from therapy. Early research indicates that a therapeutic combination of cancer vaccines with checkpoint inhibitors may lead to synergistic effects and higher response rates than monotherapy. Areas covered: This paper summarizes the previously completed and ongoing research on this exciting combination, including the use of the tumor lysate, particle-loaded dendritic cell (TLPLDC) vaccine combined with checkpoint inhibitors in advanced melanoma. Expert commentary: Increasing experience with CPIs has led to improved understanding of which patients may benefit and it is increasingly clear that the presence of a pre-existing immune response to the tumor, along with tumor-infiltrating lymphocytes, is key to the success of CPIs. One exciting possibility for the future is the addition of a cancer vaccine to CPI therapy, eliciting these crucial T cells, which can then be augmented and protected by the CPI. A number of current and future studies are addressing this very exciting combination therapy.
Collapse
Affiliation(s)
- T J Vreeland
- a Department of Surgery , Womack Army Medical Center , Fort Bragg , NC , USA
| | - G T Clifton
- b Department of Surgical Oncology , University of Texas MD Anderson Cancer Center , Houston , TX , USA
| | - G S Herbert
- c Department of Surgery , Brooke Army Medical Center , Fort Sam Houston , TX , USA
| | - D F Hale
- c Department of Surgery , Brooke Army Medical Center , Fort Sam Houston , TX , USA
| | - D O Jackson
- c Department of Surgery , Brooke Army Medical Center , Fort Sam Houston , TX , USA
| | - J S Berry
- c Department of Surgery , Brooke Army Medical Center , Fort Sam Houston , TX , USA
| | - G E Peoples
- b Department of Surgical Oncology , University of Texas MD Anderson Cancer Center , Houston , TX , USA.,d Cancer Vaccine Development Program, San Antonio, TX and Department of Surgery , Uniformed Services University of the Health Sciences , Bethesda , MD , USA
| |
Collapse
|
6
|
Berry JS, Trappey AF, Vreeland TJ, Schneble EJ, Clifton GT, Hale DF, Sears AK, Ponniah S, Shumway NM, Mittendorf EA, Peoples GE. Abstract P4-13-02: Preliminary results for the phase 1 trial of a dual HER2 peptide cancer vaccine in breast and ovarian cancer patients. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p4-13-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND: HER2 is a commonly expressed tumor-associated antigen in breast (BrCa) and ovarian cancer (OvCa) and, therefore, an attractive target for immunotherapy. We have investigated HER2-derived peptides as vaccines mixed with GM-CSF to include GP2 (a HLA-A2 and HLA-A3 restricted, CD8+ eliciting epitope) and AE37 (a HLA unrestricted, MHC class II, CD4+ eliciting epitope). Both peptide vaccines (PV) have shown clinical promise individually. There is clear rationale for combining GP2 and AE37 to elicit a more robust immune response (IR) of both CD4+ and CD8+ T cells. Here, we summarize initial toxicity (tox) and in vivo IR data from a phase 1 trial of the combined PV.
METHODS: The trial is being performed as a five cohort, 3+3 dose-escalation, safety trial. Clinically disease-free, HLA-A2+ and A3+, BrCa and OvCa patients with tumors expressing any level of HER2 (IHC 1-3+) and who have completed standard-of-care therapy are accrued. In the first cohort, three patients received six, monthly intradermal inoculations (R1-R6) of 100mcg of AE37, 100mcg of GP2, and 125mcg of GM-CSF or 100:100:125. The second cohort received 250mcg of AE37, 100mcg of GP2, and 125mcg of GM-CSF or 250:100:125. Three additional cohorts were vaccinated: 250:250:125, 500:250:125, and 500:500:125. Toxicity was graded 48-72 hours post vaccination using NCI Toxicity Criteria v4.0. After each inoculation, local reactions (LR) are measured via the sensitive ballpoint pen method and reported as the orthogonal mean (OM). IR is assessed in vivo by delayed type hypersensitivity (DTH) reactions with separate intradermal inoculations of AE37, AE36, and GP2 antigens, measured both pre-vaccination (R0) and after the vaccine series (R6) via the sensitive ballpoint pen method, and reported as the OM. Means were compared using paired t-tests.
RESULTS: 28 patients enrolled; 8 withdrew consent, 1 recurred prior to completing R6, 3 had an intercurrent illness, 14 patients completed R1-R6, and the vaccine series is ongoing in 2 patients. Six patients did not receive any inoculations and, therefore, are not included in this safety analysis. In 22 patients, the vaccine was well tolerated (max local tox: 23% Grade (Gr) 1, 73% Gr 2, 4% Gr 3; max systemic tox: 14% Gr 0, 50% Gr 1, 36% Gr 2). No dose-limiting toxicity was observed. For the 14 patients who completed the VS, the median age was 51(35-83). Breast tumor size was 3.3±1.1cm and ovarian tumor size was 10.0±2.3cm. Compared to GP2 LR at R1 (15.5±4.1mm), LR increased at R2 (31.7±5.9mm), R3 (42.9±7.4mm), R4 (35.3±7.3mm), R5 (45.0±9.9mm), and R6 (25.9±6.7mm, p = 0.17). Compared to the AE37 LR at R1 (18.5±3.8mm), LR increased at R2 (37.3±6.7mm), R3 (36.4±4.6mm), R4 (42.2±5.9mm), R5 (46.0±8.9mm), and R6 (36.2±6.6mm). Unless stated, all LR p-values < 0.05. After the VS, AE37 DTH increased from 0.0±0.0mm to 19.6±6.7mm (p<0.01), AE36 DTH increased from 0.0±0.0mm to 10.3±3.9mm (p<0.01), and GP2 DTH reactions increased from 0.3±0.2mm to 4.1±2.0mm (p = 0.056).
CONCLUSIONS: Initial results from a phase I trial of a vaccine combining GP2 and AE37 peptides show that dual administration of the peptides is well tolerated at all tested dosing levels. Additionally, the combination is capable of stimulating strong peptide-specific in vivo immune responses. Continued testing of this vaccination strategy is underway.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P4-13-02.
Collapse
Affiliation(s)
- JS Berry
- San Antonio Military Medical Center, Fort Sam Houston, TX; MD Anderson Cancer Center, Houston, TX
| | - AF Trappey
- San Antonio Military Medical Center, Fort Sam Houston, TX; MD Anderson Cancer Center, Houston, TX
| | - TJ Vreeland
- San Antonio Military Medical Center, Fort Sam Houston, TX; MD Anderson Cancer Center, Houston, TX
| | - EJ Schneble
- San Antonio Military Medical Center, Fort Sam Houston, TX; MD Anderson Cancer Center, Houston, TX
| | - GT Clifton
- San Antonio Military Medical Center, Fort Sam Houston, TX; MD Anderson Cancer Center, Houston, TX
| | - DF Hale
- San Antonio Military Medical Center, Fort Sam Houston, TX; MD Anderson Cancer Center, Houston, TX
| | - AK Sears
- San Antonio Military Medical Center, Fort Sam Houston, TX; MD Anderson Cancer Center, Houston, TX
| | - S Ponniah
- San Antonio Military Medical Center, Fort Sam Houston, TX; MD Anderson Cancer Center, Houston, TX
| | - NM Shumway
- San Antonio Military Medical Center, Fort Sam Houston, TX; MD Anderson Cancer Center, Houston, TX
| | - EA Mittendorf
- San Antonio Military Medical Center, Fort Sam Houston, TX; MD Anderson Cancer Center, Houston, TX
| | - GE Peoples
- San Antonio Military Medical Center, Fort Sam Houston, TX; MD Anderson Cancer Center, Houston, TX
| |
Collapse
|
7
|
Trappey AF, Berry JS, Vreeland TJ, Guy CT, Diane HF, Alan SK, Erika SJ, Ferrise L, Shumway NM, Papamichail M, Perez SA, Ponniah S, Mittendorf EA, Peoples GE. Abstract P4-13-05: HLA-A2 is not a prognostic indicator in breast cancer: Implications for cancer vaccine trials. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p4-13-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction
Peptide-based cancer vaccines require presentation by a specific HLA molecule. HLA-A2 is the most common class I allele in the US (40-50% of the population) and, therefore, the most commonly targeted. Our group has been investigating HER2-derived peptide vaccines administered in the adjuvant setting to high risk breast cancer patients in order to prevent disease recurrence. This study was undertaken to compare known prognostic factors and disease-free survival (DFS) in control HLA-A2+ and HLA-A2- patients in order to better define these populations for future trial design.
Methods
Our group is currently enrolling patients in a phase II trial evaluating the HER2-derived peptide vaccines, AE37 (MHC Class II, HLA-non-restricted epitope) and GP2 (MHC Class I, HLA-A2+ restricted epitope). The studies are enrolling high-risk, disease-free breast cancer patients with any level of HER2 expression (IHC 1+, 2+ or 3+) after completion of standard of care therapy. Patients are HLA-typed. HLA-A2+ patients are randomized to GP2+GM-CSF or GM-CSF alone. HLA-A2- patients are randomized to AE37+GM-CSF or GM-CSF alone. Demographics between groups are compared using chi squared or fisher exact as appropriate. DFS is compared using log rank.
Results
Thus far, 407 patients have been enrolled to the study (181 HLA-A2+ and 226 HLA-A2-). Demographics are shown in Table 1.
Table 1. Demographics (all) A2+A2-pn181226 Age (median)51500.47Node Positive62%66%0.46Grade 354%54%0.99Tumor >/ = 2 cm59%64%0.23ER/PR Negative36%38%0.59HER2 Overexpression55%51%0.39Triple Negative13%15%0.52
There are no differences between groups with respect to age, node positivity, grade, tumor size, ER/PR status, HER2 over-expression, or triple negative breast cancer. Of those enrolled, 83 HLA-A2+ patients and 109 HLA-A2- patients have been randomized to the control groups. Within the control group, there are no differences between the HLA-A2+ and HLA-A2- patients regarding age, node positivity, grade, tumor size, ER/PR status, HER2 over-expression, or triple negative breast cancer (Table 2).
With a median follow-up of 30 months, DFS is similar between A2+ and A2- control patients (83% v. 80%, p = 0.93).
Conclusions
Baseline clinico-pathologic factors are similar between HLA-A2+ and HLA-A2- breast cancer patients with no correlations to known prognostic factors. Well-matched blinded control patients treated only with GM-CSF demonstrate no differences in DFS between HLA-A2+ and HLA-A2- patients. Therefore, it does not appear that HLA-A2 status is a prognostic factor in breast cancer, and HLA-A2+ and HLA-A2- patients should be comparable in peptide-based breast cancer vaccine trials.
Table 2. Demographics (Control Group Only) A2+A2-pn83109 Age (median)51510.75Node Positive65%64%0.99Grade 359%57%0.76Tumor >/ =59%71%0.08ER/PR Negative36%38%0.84HER2 Overexpression55%46%0.19Triple Negative11%16%0.34
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P4-13-05.
Collapse
Affiliation(s)
- AF Trappey
- San Antonio Military Medical Center, San Antonio, TX; Blanchfield Army Community Hospital, Fort Campbell, KY; Cancer Vaccine Development Lab, Bethesda, MD; Cancer Immunology and Immunotherapy Center, St. Savas Hospital, Greece; MD Anderson Cancer Center, Houston, TX
| | - JS Berry
- San Antonio Military Medical Center, San Antonio, TX; Blanchfield Army Community Hospital, Fort Campbell, KY; Cancer Vaccine Development Lab, Bethesda, MD; Cancer Immunology and Immunotherapy Center, St. Savas Hospital, Greece; MD Anderson Cancer Center, Houston, TX
| | - TJ Vreeland
- San Antonio Military Medical Center, San Antonio, TX; Blanchfield Army Community Hospital, Fort Campbell, KY; Cancer Vaccine Development Lab, Bethesda, MD; Cancer Immunology and Immunotherapy Center, St. Savas Hospital, Greece; MD Anderson Cancer Center, Houston, TX
| | - CT Guy
- San Antonio Military Medical Center, San Antonio, TX; Blanchfield Army Community Hospital, Fort Campbell, KY; Cancer Vaccine Development Lab, Bethesda, MD; Cancer Immunology and Immunotherapy Center, St. Savas Hospital, Greece; MD Anderson Cancer Center, Houston, TX
| | - HF Diane
- San Antonio Military Medical Center, San Antonio, TX; Blanchfield Army Community Hospital, Fort Campbell, KY; Cancer Vaccine Development Lab, Bethesda, MD; Cancer Immunology and Immunotherapy Center, St. Savas Hospital, Greece; MD Anderson Cancer Center, Houston, TX
| | - SK Alan
- San Antonio Military Medical Center, San Antonio, TX; Blanchfield Army Community Hospital, Fort Campbell, KY; Cancer Vaccine Development Lab, Bethesda, MD; Cancer Immunology and Immunotherapy Center, St. Savas Hospital, Greece; MD Anderson Cancer Center, Houston, TX
| | - SJ Erika
- San Antonio Military Medical Center, San Antonio, TX; Blanchfield Army Community Hospital, Fort Campbell, KY; Cancer Vaccine Development Lab, Bethesda, MD; Cancer Immunology and Immunotherapy Center, St. Savas Hospital, Greece; MD Anderson Cancer Center, Houston, TX
| | - L Ferrise
- San Antonio Military Medical Center, San Antonio, TX; Blanchfield Army Community Hospital, Fort Campbell, KY; Cancer Vaccine Development Lab, Bethesda, MD; Cancer Immunology and Immunotherapy Center, St. Savas Hospital, Greece; MD Anderson Cancer Center, Houston, TX
| | - NM Shumway
- San Antonio Military Medical Center, San Antonio, TX; Blanchfield Army Community Hospital, Fort Campbell, KY; Cancer Vaccine Development Lab, Bethesda, MD; Cancer Immunology and Immunotherapy Center, St. Savas Hospital, Greece; MD Anderson Cancer Center, Houston, TX
| | - M Papamichail
- San Antonio Military Medical Center, San Antonio, TX; Blanchfield Army Community Hospital, Fort Campbell, KY; Cancer Vaccine Development Lab, Bethesda, MD; Cancer Immunology and Immunotherapy Center, St. Savas Hospital, Greece; MD Anderson Cancer Center, Houston, TX
| | - SA Perez
- San Antonio Military Medical Center, San Antonio, TX; Blanchfield Army Community Hospital, Fort Campbell, KY; Cancer Vaccine Development Lab, Bethesda, MD; Cancer Immunology and Immunotherapy Center, St. Savas Hospital, Greece; MD Anderson Cancer Center, Houston, TX
| | - S Ponniah
- San Antonio Military Medical Center, San Antonio, TX; Blanchfield Army Community Hospital, Fort Campbell, KY; Cancer Vaccine Development Lab, Bethesda, MD; Cancer Immunology and Immunotherapy Center, St. Savas Hospital, Greece; MD Anderson Cancer Center, Houston, TX
| | - EA Mittendorf
- San Antonio Military Medical Center, San Antonio, TX; Blanchfield Army Community Hospital, Fort Campbell, KY; Cancer Vaccine Development Lab, Bethesda, MD; Cancer Immunology and Immunotherapy Center, St. Savas Hospital, Greece; MD Anderson Cancer Center, Houston, TX
| | - GE Peoples
- San Antonio Military Medical Center, San Antonio, TX; Blanchfield Army Community Hospital, Fort Campbell, KY; Cancer Vaccine Development Lab, Bethesda, MD; Cancer Immunology and Immunotherapy Center, St. Savas Hospital, Greece; MD Anderson Cancer Center, Houston, TX
| |
Collapse
|
8
|
Vreeland TJ, John BS, Trappey AF, Schneble EJ, Hale DF, Clifton GT, Shumway NM, Perez SA, Papamichail M, Ponniah S, Peoples GE, Mittendorf EA. Abstract P2-14-01: Breast cancer patients with HER2 low-expression: An under-recognized group at significant risk for recurrence. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p2-14-01] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
HER2 over-expression is associated with more aggressive malignant disease. The introduction of trastuzumab and other HER2-directed therapies, however, has led to improved prognosis for patients (pts) with HER2 over-expressing (OE) tumors. Currently, no HER2-targeted therapies are available for patients with HER2 low-expressing (LE) (1+, 2+ by IHC) tumors. We are conducting a randomized, controlled Phase II trial of multiple peptide vaccines enrolling patients with any level of HER2 expression (1+, 2+ and 3+). Here, we report survival data based on levels of HER2 expression in our unvaccinated, control pts.
Methods:
After standard of care therapy, disease-free, high-risk BCa pts were randomized to receive either peptide+GM-CSF (Vaccine Group, VG) or GM-CSF alone (Control Group, CG) in six, monthly doses followed by four boosters every six months. Pts were prospectively followed for recurrence. Demographic information was available for all pts and was compared between groups using chi square or fisher exact tests. Disease-Free Survival (DFS) was compared using log rank.
Results:
To date, we have enrolled 196 pts in the CG. 96 pts had HER2 OE tumors, 100 had LE tumors. The only significant demographic difference between the CG OE and LE groups was more ER/PR positive patients in LE (LE 72% vs OE 51%, p = 0.008). 83% of CG OE pts received trastuzumab, 3% of CG LE pts received trastuzumab. At a median f/u of 30 mo, DFS was significantly higher for CG OE vs CG LE (92.5% v 65.5%, p = 0.001).
Conclusions:
In the cohort of control pts from our ongoing vaccine trial, conducted in an era when Tz has been standard of care therapy for patients with HER2 OE tumors, we have shown that HER2 LE pts are at higher risk of recurrence than OE pts, despite having more ER/PR positive. This calls for increased efforts to develop novel therapies for patients with HER2 LE disease. We have previously shown a trend towards increased DFS with the HER2 vaccines, AE37 (p = 0.13, median f/u 22 mo) and E75 (p = 0.16, median f/u 60mo) in HER2 LE pts, suggesting that these vaccines may represent one such novel therapeutic approach.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P2-14-01.
Collapse
Affiliation(s)
- TJ Vreeland
- San Antonio Military Medical Center, San Antonio, TX; Blanchfield Community Army Hospital, FT Campbell, KY; MD Anderson Cancer Center, Houston, TX; United States Military Cancer Institute, USUHS, Bethesda, MD; Cancer Immunology and Immunotherapy Center, St Savas Hospital, Athens, Greece
| | - BS John
- San Antonio Military Medical Center, San Antonio, TX; Blanchfield Community Army Hospital, FT Campbell, KY; MD Anderson Cancer Center, Houston, TX; United States Military Cancer Institute, USUHS, Bethesda, MD; Cancer Immunology and Immunotherapy Center, St Savas Hospital, Athens, Greece
| | - AF Trappey
- San Antonio Military Medical Center, San Antonio, TX; Blanchfield Community Army Hospital, FT Campbell, KY; MD Anderson Cancer Center, Houston, TX; United States Military Cancer Institute, USUHS, Bethesda, MD; Cancer Immunology and Immunotherapy Center, St Savas Hospital, Athens, Greece
| | - EJ Schneble
- San Antonio Military Medical Center, San Antonio, TX; Blanchfield Community Army Hospital, FT Campbell, KY; MD Anderson Cancer Center, Houston, TX; United States Military Cancer Institute, USUHS, Bethesda, MD; Cancer Immunology and Immunotherapy Center, St Savas Hospital, Athens, Greece
| | - DF Hale
- San Antonio Military Medical Center, San Antonio, TX; Blanchfield Community Army Hospital, FT Campbell, KY; MD Anderson Cancer Center, Houston, TX; United States Military Cancer Institute, USUHS, Bethesda, MD; Cancer Immunology and Immunotherapy Center, St Savas Hospital, Athens, Greece
| | - GT Clifton
- San Antonio Military Medical Center, San Antonio, TX; Blanchfield Community Army Hospital, FT Campbell, KY; MD Anderson Cancer Center, Houston, TX; United States Military Cancer Institute, USUHS, Bethesda, MD; Cancer Immunology and Immunotherapy Center, St Savas Hospital, Athens, Greece
| | - NM Shumway
- San Antonio Military Medical Center, San Antonio, TX; Blanchfield Community Army Hospital, FT Campbell, KY; MD Anderson Cancer Center, Houston, TX; United States Military Cancer Institute, USUHS, Bethesda, MD; Cancer Immunology and Immunotherapy Center, St Savas Hospital, Athens, Greece
| | - SA Perez
- San Antonio Military Medical Center, San Antonio, TX; Blanchfield Community Army Hospital, FT Campbell, KY; MD Anderson Cancer Center, Houston, TX; United States Military Cancer Institute, USUHS, Bethesda, MD; Cancer Immunology and Immunotherapy Center, St Savas Hospital, Athens, Greece
| | - M Papamichail
- San Antonio Military Medical Center, San Antonio, TX; Blanchfield Community Army Hospital, FT Campbell, KY; MD Anderson Cancer Center, Houston, TX; United States Military Cancer Institute, USUHS, Bethesda, MD; Cancer Immunology and Immunotherapy Center, St Savas Hospital, Athens, Greece
| | - S Ponniah
- San Antonio Military Medical Center, San Antonio, TX; Blanchfield Community Army Hospital, FT Campbell, KY; MD Anderson Cancer Center, Houston, TX; United States Military Cancer Institute, USUHS, Bethesda, MD; Cancer Immunology and Immunotherapy Center, St Savas Hospital, Athens, Greece
| | - GE Peoples
- San Antonio Military Medical Center, San Antonio, TX; Blanchfield Community Army Hospital, FT Campbell, KY; MD Anderson Cancer Center, Houston, TX; United States Military Cancer Institute, USUHS, Bethesda, MD; Cancer Immunology and Immunotherapy Center, St Savas Hospital, Athens, Greece
| | - EA Mittendorf
- San Antonio Military Medical Center, San Antonio, TX; Blanchfield Community Army Hospital, FT Campbell, KY; MD Anderson Cancer Center, Houston, TX; United States Military Cancer Institute, USUHS, Bethesda, MD; Cancer Immunology and Immunotherapy Center, St Savas Hospital, Athens, Greece
| |
Collapse
|
9
|
Hale DF, Vreeland TJ, Perez SA, Berry JS, Ardavanis A, Trappey AF, Tzonis P, Sears AK, Clifton GT, Shumway NM, Papamichail M, Ponniah S, Peoples GE, Mittendorf EA. Abstract P5-16-05: The combination of trastuzumab and HER2-directed peptide vaccines is safe in HER2-expressing breast cancer patients. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p5-16-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Cardiotoxicity is the most concerning toxicity associated with the commonly used HER2-directed immunotherapy, trastuzumab (Tz). In general, a significant decline of left ventricular ejection fraction (EF) in asymptomatic patients is accepted as a decrease of at least 10% or an absolute value of below 50%. We are currently conducting multiple trials of HER2-directed peptide vaccines, often given either concurrently or in close temporal proximity to Tz. This has raised the issue that combining therapies could increase the risk of cardio-toxicity. Here, we present safety data from multiple trials in which the combination of these HER2-directed therapies was administered.
Methods: Phase I and II trials were conducted in disease-free breast cancer patients after completion of chemotherapy when indicated. Patients (pts) who were determined by treating oncologists to qualify for Tz received this therapy per standard-of-care. These pts were enrolled onto HER2-directed peptide vaccine trials per each trial's inclusion criteria, with vaccinated (VG) pts receiving peptide + GM-CSF and control (CG) pts receiving GM-CSF alone. All patients were monitored for local and systemic toxicity to peptide inoculations (graded by the NCI's Common Terminology Criteria for Adverse Events). In addition, patients who received Tz had EF tracked through either echocardiogram or MUGA according to local standard of practice. Our database was queried for patients who received Tz and peptide, and had documented measures of EF pre-vaccine (Pre), during vaccine (D) and post-vaccine (Post). These pts were then placed in two groups based on the timing of Tz and vaccine therapy: concurrent(C) group and sequential(S) group. Mean EF at each time point was compared using a t-test.
Results: Overall, the peptide vaccines were well tolerated (max local tox: 1% Grade 0, 65% Gr 1, 33% Gr 2, 1% Gr 3; max systemic tox: 19% Gr 0, 63% Gr 1, 18% Gr 2, 0% Gr 3). These toxicities are likely secondary to the GM-CSF immunoadjuvant as control pts receiving GM-CSF alone have similar toxicity profiles (max local tox: 0% Gr 0, 76% Gr 1, 23% Gr 2, 1% Gr 3; max systemic tox: 20% Gr 0, 65% Gr 1, 15% Gr 2, 0% Gr 3). There have been no serious or non-serious cardiac-related adverse events in our trials. In total, 71 pts treated with Tz and enrolled in a vaccine trial had EF measurements available for analysis; 54 in the S group (35 VG, 19 CG) and 17 in the C group (10 VG, 7 CG). Overall, neither VG nor CG pts had significant changes in EF (VG Pre: 65±0.8%, D: 63±0.9%, Post: 64±0.3%; CG Pre: 63±1.2%, D: 64±1.8%, Post: 63±1.1%). Separating VG pts into C and S pts, there were again no significant changes in EF, (C Pre: 65±1.0%, D: 63±1.0%, Post: 63±1.4%; S Pre: 65±1.7%, D: 61±1.3%, Post: 65±1.8%).
Conclusions: HER2-directed peptide vaccines are safe and well tolerated. Initial data indicate that the combination of Tz and HER2-directed peptide vaccines, whether concurrent or sequential, does not cause significant cardiac toxicities as measured by changes in the EF during and after therapy. We will continue to track this safety data to confirm early findings as we pursue additional combination trials.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P5-16-05.
Collapse
Affiliation(s)
- DF Hale
- Brooke Army Medical Center, San Antonio, TX; Cancer Immunology and Immunotherapy Center, Athens, Greece; MD Anderson Cancer Center, Houston, TX; Uniformed Services University of the Health Sciences, Bethesda, MD
| | - TJ Vreeland
- Brooke Army Medical Center, San Antonio, TX; Cancer Immunology and Immunotherapy Center, Athens, Greece; MD Anderson Cancer Center, Houston, TX; Uniformed Services University of the Health Sciences, Bethesda, MD
| | - SA Perez
- Brooke Army Medical Center, San Antonio, TX; Cancer Immunology and Immunotherapy Center, Athens, Greece; MD Anderson Cancer Center, Houston, TX; Uniformed Services University of the Health Sciences, Bethesda, MD
| | - JS Berry
- Brooke Army Medical Center, San Antonio, TX; Cancer Immunology and Immunotherapy Center, Athens, Greece; MD Anderson Cancer Center, Houston, TX; Uniformed Services University of the Health Sciences, Bethesda, MD
| | - A Ardavanis
- Brooke Army Medical Center, San Antonio, TX; Cancer Immunology and Immunotherapy Center, Athens, Greece; MD Anderson Cancer Center, Houston, TX; Uniformed Services University of the Health Sciences, Bethesda, MD
| | - AF Trappey
- Brooke Army Medical Center, San Antonio, TX; Cancer Immunology and Immunotherapy Center, Athens, Greece; MD Anderson Cancer Center, Houston, TX; Uniformed Services University of the Health Sciences, Bethesda, MD
| | - P Tzonis
- Brooke Army Medical Center, San Antonio, TX; Cancer Immunology and Immunotherapy Center, Athens, Greece; MD Anderson Cancer Center, Houston, TX; Uniformed Services University of the Health Sciences, Bethesda, MD
| | - AK Sears
- Brooke Army Medical Center, San Antonio, TX; Cancer Immunology and Immunotherapy Center, Athens, Greece; MD Anderson Cancer Center, Houston, TX; Uniformed Services University of the Health Sciences, Bethesda, MD
| | - GT Clifton
- Brooke Army Medical Center, San Antonio, TX; Cancer Immunology and Immunotherapy Center, Athens, Greece; MD Anderson Cancer Center, Houston, TX; Uniformed Services University of the Health Sciences, Bethesda, MD
| | - NM Shumway
- Brooke Army Medical Center, San Antonio, TX; Cancer Immunology and Immunotherapy Center, Athens, Greece; MD Anderson Cancer Center, Houston, TX; Uniformed Services University of the Health Sciences, Bethesda, MD
| | - M Papamichail
- Brooke Army Medical Center, San Antonio, TX; Cancer Immunology and Immunotherapy Center, Athens, Greece; MD Anderson Cancer Center, Houston, TX; Uniformed Services University of the Health Sciences, Bethesda, MD
| | - S Ponniah
- Brooke Army Medical Center, San Antonio, TX; Cancer Immunology and Immunotherapy Center, Athens, Greece; MD Anderson Cancer Center, Houston, TX; Uniformed Services University of the Health Sciences, Bethesda, MD
| | - GE Peoples
- Brooke Army Medical Center, San Antonio, TX; Cancer Immunology and Immunotherapy Center, Athens, Greece; MD Anderson Cancer Center, Houston, TX; Uniformed Services University of the Health Sciences, Bethesda, MD
| | - EA Mittendorf
- Brooke Army Medical Center, San Antonio, TX; Cancer Immunology and Immunotherapy Center, Athens, Greece; MD Anderson Cancer Center, Houston, TX; Uniformed Services University of the Health Sciences, Bethesda, MD
| |
Collapse
|
10
|
Sears AK, Clifton GT, Vreeland TJ, Hale DF, Ponniah S, Mittendorf EA, Peoples GE. OT3-01-18: Combination Immunotherapy with Trastuzumab and the HER2 Vaccine E75 in Low and Intermediate HER2−Expressing Breast Cancer Patients To Prevent Recurrence. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-ot3-01-18] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
In a phase II trial, the HER2−derived E75 vaccine administered with the immunoadjuvant GM-CSF has been shown to reduce breast cancer recurrence in the adjuvant setting, with a greater benefit seen in patients with low levels of HER2 expression (IHC 1+ or 2+). There has also been recent suggestion that patients with low HER2 expression may also benefit from trastuzumab. Preclinical testing of the combination of trastuzumab and the E75 vaccine has shown a synergism with combinational therapy. Finally, from our phase II trials of cytotoxic T cell-eliciting peptide vaccines, sequential treatment with trastuzumab and HER2 vaccination has resulted in no recurrences in 30 patients with a median follow-up of 48 months. Based on these results, we have designed a trial to evaluate the ability of the combination of trastuzumab and the E75 vaccine to prevent breast cancer recurrence.
Trial Design: This study will be a multi-center, prospective, randomized, single-blinded, phase II trial evaluating trastuzumab + E75+GM-CSF (immunoadjuvant) vs. trastuzumab + GM-CSF alone (no E75) in the adjuvant setting in breast cancer patients. Eligible patients include node positive (or node negative if negative for both ER and PR) disease-free breast cancer patients with low or intermediate levels of HER2 expression (IHC 1+ or 2+) and adequate cardiac function (LVEF >50%). Patients must be HLA-A2/A3+ (E75 is HLA-A2/A3-restricted). Patients will be enrolled after completing standard of care multi-modal therapy and randomized between the two treatment arms with stratification by HER2 expression (1+ or 2+) and nodal status (N0, N1, N2, or N3). Vaccinations (E75+GM-CSF or GM-CSF alone) will be administered as six monthly intradermal inoculations concurrently with trastuzumab therapy. The primary efficacy endpoint is to compare disease-free survival (DFS) between treatment arms at 24 months. Secondary objectives will include evaluation of cardiac toxicity from combination therapy (periodic cardiac assessment with MUGA or ECHO), DFS at 36 months, and immunologic responses to vaccination. From previously published experience with trastuzumab, we expect a recurrence rate of 15% in trastuzumab (plus GM-CSF) treated patients and anticipate that the combination of trastuzumab with E75+GM-CSF will reduce this recurrence rate to 5%. In order to show a statistical difference between these recurrence rates, we plan to enroll 150 patients per treatment arm (300 total) with a type I error rate of 5% and 80% power to detect the primary endpoint. Trial accrual is anticipated to begin in January 2012, with a two year period of enrollment followed by a three year follow-up period.
Conclusion: We hypothesize that combination adjuvant immunotherapy with trastuzumab and E75 vaccination will result in a greater reduction in breast cancer recurrence than trastuzumab therapy alone and have designed a multi-center, prospective, randomized, single-blinded, phase II trial evaluating the efficacy of this immunotherapy combination.
Contact Information: This trial is sponsored by Genentech and RXi Pharmaceuticals through the Henry M. Jackson Foundation.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr OT3-01-18.
Collapse
Affiliation(s)
- AK Sears
- 1Brooke Army Medical Center, Ft. Sam Houston, TX; Uniformed Services University of the Health Sciences, USMCI, Bethesda, MD; UTM.D. Anderson Cancer Center, Houston, TX
| | - GT Clifton
- 1Brooke Army Medical Center, Ft. Sam Houston, TX; Uniformed Services University of the Health Sciences, USMCI, Bethesda, MD; UTM.D. Anderson Cancer Center, Houston, TX
| | - TJ Vreeland
- 1Brooke Army Medical Center, Ft. Sam Houston, TX; Uniformed Services University of the Health Sciences, USMCI, Bethesda, MD; UTM.D. Anderson Cancer Center, Houston, TX
| | - DF Hale
- 1Brooke Army Medical Center, Ft. Sam Houston, TX; Uniformed Services University of the Health Sciences, USMCI, Bethesda, MD; UTM.D. Anderson Cancer Center, Houston, TX
| | - S Ponniah
- 1Brooke Army Medical Center, Ft. Sam Houston, TX; Uniformed Services University of the Health Sciences, USMCI, Bethesda, MD; UTM.D. Anderson Cancer Center, Houston, TX
| | - EA Mittendorf
- 1Brooke Army Medical Center, Ft. Sam Houston, TX; Uniformed Services University of the Health Sciences, USMCI, Bethesda, MD; UTM.D. Anderson Cancer Center, Houston, TX
| | - GE Peoples
- 1Brooke Army Medical Center, Ft. Sam Houston, TX; Uniformed Services University of the Health Sciences, USMCI, Bethesda, MD; UTM.D. Anderson Cancer Center, Houston, TX
| |
Collapse
|
11
|
Wie CR, Jones T, Tombrello TA, Vreeland T, Xiong F, Zhu Z, Burns G, Dacol FH. Radiation Defect-Induced Lattice Contraction of InP. ACTA ACUST UNITED AC 2011. [DOI: 10.1557/proc-74-517] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
AbstractWe studied the lattice strain induced in the MeV ion bombarded InP crystals and the annealing behaviors of lattice strain, Raman line shift, and linewidth. The lattice spacing for the planes parallel to the surface decreases as a result of irradiation, and amounts to a strain of −0.061% for (100) face, −0.056% for (110) face, and −0.050% for (111) face for 15 MeV Cl bombarded samples to a dose of 1.25E15 ions/cm2. The negative lattice strain, Raman line shift, and line width completely recover at 450°C, and show a major recovery stage at 250°C – 350°C.
Collapse
|
12
|
Abstract
AbstractThis paper presents the methodology employed in the determination of the stress tensor for thin crystalline films using x-ray rocking curves. Use of the same equipment for the determination of the average stress in poly- or non-crystalline thin films attached to a crystalline substrate is also discussed. In this case the lattice curvature of the substrate is determined by measurement of the shift In the Bragg peak with lateral position in the substrate.Strains in single crystal layers may be measured using Bragg diffraction from the layers and from the substrate or a reference crystal, with the highest strain sensitivity of any known technique. The difference in Bragg angles for a strained and an unstrained crystal is related to the change in d spacing of the Bragg planes, and the elastic strain is related to'this angular difference. The separation of two peaks on an x-ray rocking curve is generally not equal to the difference in Bragg angles of two diffracting crystals, so diffractometer measurements must be carefully Interpreted in order to obtain x-ray strains in crystalline films (x-ray strains are strains relative to the reference crystal). The unstrained d spacings of the film and the d spacings of the reference crystal must be known to obtain the elastic strains in the film, from which the stress tensor is determined.
Collapse
|
13
|
Affiliation(s)
- R. C. Blish
- a W. M. Keck Laboratory of Engineering Materials , California Institute of Technology , Pasadena
- b Bell Telephone Laboratories , Murray Hill. , New Jersey
| | - T. Vreeland
- a W. M. Keck Laboratory of Engineering Materials , California Institute of Technology , Pasadena
| |
Collapse
|
14
|
Tong W, Ravichandran G, Christman T, Vreeland T. Processing SiC-particulate reinforced titanium-based metal matrix composites by shock wave consolidation. ACTA ACUST UNITED AC 1995. [DOI: 10.1016/0956-7151(95)90279-1] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
15
|
Tsai CJ, Vreeland T, Atwater HA. Defect formation and diffusion mechanism in ion-assisted molecular-beam epitaxy. Phys Rev B Condens Matter 1992; 46:7103-7109. [PMID: 10002416 DOI: 10.1103/physrevb.46.7103] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/12/2023]
|
16
|
Krueger BR, Mutz AH, Vreeland T. Shock-induced and self-propagating high-temperature synthesis reactions in two powder mixtures: 5:3 Atomic ratio Ti/Si and 1:1 Atomic ratio Ni/Si. ACTA ACUST UNITED AC 1992. [DOI: 10.1007/bf02660851] [Citation(s) in RCA: 41] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
17
|
|
18
|
Wie CR, Tombrello TA, Vreeland T. MeV ion damage in GaAs single crystals: Strain saturation and role of nuclear and electronic collisions in defect production. Phys Rev B Condens Matter 1986; 33:4083-4089. [PMID: 9938828 DOI: 10.1103/physrevb.33.4083] [Citation(s) in RCA: 28] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/11/2023]
|
19
|
|
20
|
Hamill GP, Vreeland T. Diffracted beam–transmitted beam Borrmann X-ray topography in copper. A novel method of stereo depth topography. J Appl Crystallogr 1979. [DOI: 10.1107/s0021889879012668] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
21
|
Jassby K, Vreeland T. Investigation of pyramidal edge and screw dislocation mobility in zinc by a compressional stress pulse technique. ACTA ACUST UNITED AC 1977. [DOI: 10.1016/0025-5416(77)90187-2] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
22
|
|
23
|
|
24
|
|
25
|
|
26
|
|
27
|
|
28
|
|
29
|
Moon D, Vreeland T. Stress dependence of mobile dislocation density and dislocation velocity from Lüders band front propagation velocity. ACTA ACUST UNITED AC 1968. [DOI: 10.1016/0036-9748(68)90164-6] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
30
|
|
31
|
|
32
|
|
33
|
|